Mechanism · Research Data · Side Effects · No Doses
TL;DR: Tesamorelin is a modified GHRH analogue with much stronger human evidence than most compounds in this research library. Its established trial evidence concerns excess visceral abdominal fat in people with HIV-associated lipodystrophy, not general weight loss. It works through the pituitary GH and IGF-1 axis, and separate research has also examined cognition in older adults. It is not licensed as a medicine in Ireland or the wider EU.
| Evidence Type | Status |
|---|---|
| Human RCT | ✔ |
| Observational | ✔ |
| Animal Studies | ✔ |
| In Vitro | ✔ |
| Regulatory Approval | ✔ |
Note: Regulatory approval refers to FDA approval in the United States (Egrifta / Egrifta SV, 2010) for a specific indication. Tesamorelin is not approved by the EMA and is not licensed or HPRA-approved for use in Ireland or the wider EU.
The primary and most robustly documented research area for Tesamorelin is its effect on visceral adipose tissue. The pivotal Phase 3 trials reported by Falutz and colleagues, alongside related work published in the New England Journal of Medicine, demonstrated statistically significant reductions in VAT of approximately 15-20% over 26-week treatment periods, with minimal corresponding change in subcutaneous adipose tissue — a selectivity that distinguishes Tesamorelin from generalised weight-loss interventions.
Alongside VAT reduction, the Falutz et al. trial programme reported improvements in triglyceride levels among treated patients, alongside the expected elevation in IGF-1 as a pharmacodynamic marker of GHRH receptor engagement. These metabolic findings have made Tesamorelin a reference compound in research examining the relationship between visceral fat, GH axis activity, and cardiometabolic risk markers.
A separate and notable strand of research, led by Baker and Craft and published in Archives of Neurology in 2012, examined GHRH/Tesamorelin administration in older adults with mild cognitive impairment (MCI). This work reported improvements on cognitive measures including executive function and verbal memory following GHRH analogue administration, generating research interest in the GH/IGF-1 axis as a modulator of cognitive ageing, independent of the lipodystrophy indication.
Across the trial programme, Tesamorelin consistently restored IGF-1 levels toward the normal physiological range in populations with GH axis suppression, providing a well-characterised pharmacodynamic marker that is frequently used in research to confirm target engagement and dose-response relationships.
| Study / Model | Reported Effect |
|---|---|
| Falutz J et al. — Phase 3 RCT, HIV-associated lipodystrophy | Visceral adipose tissue reduced by approximately 15-20% versus placebo, with no significant change in subcutaneous fat. |
| Falutz J et al. — Phase 3 lipid sub-analysis | Statistically significant improvement in triglyceride levels; consistent elevation of IGF-1 versus placebo. |
| Baker LD, Craft S et al. — GHRH/Tesamorelin in MCI (HIV-negative cohort) | Improvements on cognitive measures including executive function and delayed verbal memory versus placebo. |
| Baker LD, Craft S et al. — GHRH/Tesamorelin in MCI (HIV-positive cohort) | Similar direction of cognitive benefit reported, supporting the GH/IGF-1 axis as a research target in cognitive ageing. |
| Long-term extension studies (Egrifta programme) | Sustained VAT reduction with continued treatment; effect reported to reverse toward baseline after discontinuation. |
Personal experience, not guidance. I have used Tesamorelin. As with everything else on this site, the amount, the frequency and the duration are not going on the page. They belong with the doctor who reads my bloods.
What I watched was the bloods, because that is the only part of this anyone can actually verify, and because a growth-hormone-axis compound is one of the few in this space where there is a real reason to keep an eye on glucose specifically. My list, in the order I care about it: HDL first, then LDL and ApoB, triglycerides, haematocrit, blood pressure, liver, glucose and kidney markers, then sleep and how I feel day to day. I am not publishing what those numbers did either. One person, no control group, and full knowledge of what he had taken is not evidence of anything about a compound, and treating it as evidence is exactly what I am trying to avoid doing here.
The honest version is that this sits a long way down the list. I went from over 90kg to 72kg on a calorie deficit, enough protein, a four-day resistance split and 10,000 steps most days. I paid a personal trainer thousands to learn that. Before anything gets added on top of the basics I ask whether it genuinely improves the result enough to justify the health cost, the financial cost, the complexity and the uncertainty. Usually it does not.
This site does not publish doses, durations or frequencies for any compound. Published research protocols for this compound vary considerably between studies in design, intensity and duration. Those details are not something to copy from a fitness website — anyone researching this compound should read the primary literature directly and talk to a doctor who knows their bloods.
Tesamorelin has a documented safety profile from its FDA-approved product labelling. The Egrifta label carries a warning regarding fluid retention and advises caution in patients with disease activity of active malignancy, reflecting theoretical concerns around GH/IGF-1 axis stimulation in the presence of active cancer — patients with a history of malignancy require careful clinical assessment before use. These documented signals distinguish Tesamorelin from earlier-stage research peptides that lack a real-world adverse event record.
Reconstitution calculator, dosing-frequency planner and cycle-length calculator. No signup required.
Open the Peptide CalculatorsTracking food too? Free calorie counter with barcode scanner →